Strong Generics-led finish to 2023
22/02/24 -"Hikma’s H2 23 results exceeded the street’s expectations, with Generics being the lead performer. Even the 2024 guidance was largely in line with the consensus estimates. The results were cheered by ..."
Pages
55
Language
English
Published on
22/02/24
You may also be interested by these reports :
07/10/26
Our estimates are already at the higher end, with our target price significantly benefitting from increased NAV and DCF estimates, as well as a ...
30/09/26
Lundbeck, as per Bloomberg, is pursuing endocrine- and neurology-focused Xeris Biopharma, whose market cap is c.28% of that of Lundbeck. Considering ...
24/09/26
A years/decades long search for revolutionary multi-blockbuster drug(s), a phenomenal run for some years and then concerns sprout around ...
21/09/26
Novo’s CMD announcements, including the diversification plan and a vague mid-term sales target, disappointed investors. Against the backdrop of ...